Shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) have been assigned an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Sonoma Pharmaceuticals’ rating score has declined by 100% from 90 days ago as a result of various analysts’ ratings changes.
Brokerages have set a 12 month consensus price objective of $9.00 for the company and are expecting that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also given Sonoma Pharmaceuticals an industry rank of 102 out of 265 based on the ratings given to related companies.
Several brokerages recently weighed in on SNOA. Zacks Investment Research raised shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a research report on Wednesday, January 10th. Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective (down previously from $11.00) on shares of Sonoma Pharmaceuticals in a research report on Wednesday, February 14th. Finally, ValuEngine raised shares of Sonoma Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Wednesday, February 7th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.10). The company had revenue of $4.84 million for the quarter, compared to analyst estimates of $4.50 million. Sonoma Pharmaceuticals had a negative return on equity of 70.95% and a negative net margin of 70.46%. sell-side analysts forecast that Sonoma Pharmaceuticals will post -2.86 earnings per share for the current year.
An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) by 58.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 58,602 shares of the company’s stock after acquiring an additional 21,680 shares during the quarter. Renaissance Technologies LLC owned approximately 1.26% of Sonoma Pharmaceuticals worth $319,000 at the end of the most recent reporting period. 13.24% of the stock is currently owned by institutional investors and hedge funds.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.